-
Article
Open AccessVirus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies
MUC16 is a heavily glycosylated cell surface mucin cleaved in the tumor microenvironment to shed CA125. CA125 is a serum biomarker expressed by > 95% of non-mucinous advanced stage epithelial ovarian cancers. ...
-
Article
Open AccessLocalization of Salmonella and albumin-IL-2 to the tumor microenvironment augments anticancer T cell immunity
For centuries, microbial-based agents have been investigated as a therapeutic modality for the treatment of cancer. In theory, these methods would be cheap to produce, broadly applicable in a wide array of can...
-
Article
Open AccessControl of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine
Human Papillomavirus type 16 (HPV16) has been associated with a subset of head and neck cancers. Two HPV encoded oncogenic proteins, E6 and E7, are important for the malignant progression of HPV-associated can...
-
Article
Open AccessA novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions
The spread of SARS-CoV-2, the virus that causes Coronavirus Disease 2019 (COVID-19), has been characterized as a worldwide pandemic. Currently, there are few preclinical animal models that suitably represent i...
-
Article
NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells
A major factor impeding the success of numerous therapeutic approaches in cancer is the immunosuppressive nature of the tumor microenvironment (TME). Hence, methods capable of reverting tumor immunosuppression...
-
Article
Open AccessTLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy
The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy c...
